A Robust Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T- and B-Cell Response Is Associated With Early Viral Clearance in SARS-CoV-2 Omicron-Infected Immunocompromised Individuals

Author:

Vergouwe Magda12ORCID,Biemond Jason J12,van der Straten Karlijn234,van Pul Lisa25,Kerster Gius23,Claireaux Mathieu23,Burger Judith A23,van Dort Karel A25,Kootstra Neeltje A25,Jonges Marcel3,Welkers Matthijs R A3,Hazenberg Mette D267,Peters-Sengers Hessel1,van Gils Marit J23,Wiersinga W Joost124,Birnie Emma124ORCID,de Bree Godelieve J24, ,Olijhoek Wouter,Kalmoua Zakaria,Appelman Brent,Zaaijer Hans L,van Ittersum Frans J,van der Loeff Maarten F Schim,Bomers Marije K,Kersten Marie José,Heijmans Jarom,van der Valk Marc,de Boer Mark G J

Affiliation:

1. Center for Experimental and Molecular Medicine, Amsterdam University Medical Center, location AMC, University of Amsterdam , Amsterdam , The Netherlands

2. Amsterdam institute for Infection and Immunity, Infectious Diseases

3. Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Center, University of Amsterdam , Amsterdam , The Netherlands

4. Division of Infectious Diseases, Department of Medicine, Amsterdam University Medical Center, University of Amsterdam , Amsterdam , The Netherlands

5. Department of Experimental Immunology, Amsterdam University Medical Center, University of Amsterdam , Amsterdam , The Netherlands

6. Department of Hematology, Amsterdam University Medical Center, University of Amsterdam , Amsterdam , The Netherlands

7. Department of Hematopoiesis, Sanquin Research , Amsterdam , The Netherlands

Abstract

Abstract Background The immunological determinants of delayed viral clearance and intrahost viral evolution that drive the development of new pathogenic virus strains in immunocompromised individuals are unknown. Therefore, we longitudinally studied severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific immune responses in relation to viral clearance and evolution in immunocompromised individuals. Methods Among Omicron-infected immunocompromised individuals, we determined SARS-CoV-2–specific T- and B-cell responses, anti-spike immunoglobulin G (IgG) and IgG3 titers, neutralization titers, and monoclonal antibody (mAb) resistance–associated mutations. The 28-day post-enrollment nasopharyngeal specimen defined early (reverse-transcription polymerase chain reaction [RT-PCR] negative ≤28 days) or late (RT-PCR positive >28 days) viral clearance. Results Of 30 patients included (median age, 61.9 [interquartile range, 47.4–72.3] years; 50% females), 20 (66.7%) received mAb therapy. Thirteen (43.3%) demonstrated early and 17 (56.7%) late viral clearance. Patients with early viral clearance and patients without resistance-associated mutations had significantly higher baseline interferon-γ release, and patients with early viral clearance had a higher frequency of SARS-CoV-2–specific B cells at baseline. In non-mAb-treated patients, day 7 IgG and neutralization titers were significantly higher in those with early versus late viral clearance. Conclusions An early robust adaptive immune response is vital for efficient viral clearance and associated with less emergence of mAb resistance–associated mutations in Omicron-infected immunocompromised patients. This emphasizes the importance of early SARS-CoV-2–specific T- and B-cell responses and thereby provides a rationale for development of novel therapeutic approaches.

Funder

Netherlands Organization for Health Research and Development

Netherlands Organization for Scientific Research

VENI

VIDI

Talud Foundation

Amsterdam UMC Corona Research Fund

Publisher

Oxford University Press (OUP)

Reference41 articles.

1. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review;Wiersinga;JAMA,2020

2. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis;Lee;BMJ,2022

3. COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada;Bahremand;Lancet Reg Health Am,2023

4. Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies;Lee;Cancer Discov,2022

5. Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses;Lyudovyk;Cancer Cell,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3